Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

20191,194 citationsJournal Articlebronze Open Access

Authors

Alexander E. Perl · UPMC Hillman Cancer Center

Giovanni Martinelli

Jörge E. Cortes · The University of Texas MD Anderson Cancer Center

Andreas Neubauer · Universitätsklinikum Gießen und Marburg

Ellin Berman · Memorial Sloan Kettering Cancer Center

Stefania Paolini · GNA University

Pau Montesinos

Maria R. Baer

Abstract

Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory <i>FLT3</i>-mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials.gov number, NCT02421939.).

Topics & Keywords

Acute Myeloid Leukemia Research Chronic Myeloid Leukemia Treatments Myeloproliferative Neoplasms: Diagnosis and Treatment

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 18, pp. 1728-1740

DOI: 10.1056/nejmoa1902688

Field-Weighted Citation Impact: 98.44

Command Palette

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Authors

Abstract

Topics & Keywords

Publication Details